Company Overview
Astellas Pharma Europe Ltd. is listed at the official companies registry as Active Private Limited Company. The company was incorporated on Thursday 29 March 1990, so this is a well established company. Astellas Pharma Europe Ltd. has been in business for 36 years. The accounts status is full and the accounts are next due on Thursday 31 December 2026.
Registered Address

300 Dashwood Lang Road, Bourne Business Park, Addlestone, KT15 2NX
Credit Reports Available

These credit rating reports are available now:


Credit Analysts Report
Get Report >>

Standard Credit Report
Get Report >>

Basic Credit Report
Get Report >>

24/7 credit rating data feed - no UK company credit reports are updated faster

Companies House Data
Company NameASTELLAS PHARMA EUROPE LTD.
Company Number02486792
Registered Office Address300 Dashwood Lang Road
 Bourne Business Park
 KT15 2NX
Company CategoryPrivate Limited Company
Company StatusActive
Country of OriginUnited Kingdom
Incorporation Date29/03/1990
Accounting Reference Date Day31
Accounting Reference Date Month3
Accounts Next Due Date31/12/2026
Accounts Last Made Up Date31/03/2025
Accounts Account CategoryFULL
Returns Next Due Date23/03/2017
Returns Last Made Up Date23/02/2016
Directors & Members
Show Resigned
Martina Dempsey - Director
(Irish, 61 years old, born December 1965)
Appointed 01 April 2023
 Active
Lesley Flowerdew - Director
(British, 59 years old, born October 1967)
Appointed 01 April 2022
 Active
Richard Gane - Director
(British, 57 years old, born March 1969)
Appointed 15 November 2021
 Active
Secretaries
Show Resigned
Other Company Directorships
Martina Dempsey
No companies found
Lesley Flowerdew
QUETHERA LIMITED
Richard Gane
No companies found
Balance Sheet Unlock full report
Accounts Date 31-Mar-2025 31-Mar-2014 31-Mar-2013
Balance Sheet
Fixed Assets 79,032,654 79,032,654 135,469,720
Current Assets 207,288,660 207,288,660 121,385,690
Creditors Due Within One Year 146,634,686 146,634,686 160,576,021
Working Cap 60,653,974 60,653,974 -39,190,331
Total Assets Less Current Liabilities 139,686,628 139,686,628 96,279,389
Long-term Liabilities 6,282,796 6,282,796 7,309,629
Net Assets 133,403,832 133,403,832 88,969,760
Share Capital & Reserves
Share Cap 108,525,004 108,525,004 104,665,588
Profit & Loss Reserves -93,163,274 -93,163,274 -59,441,816
Other Reserves 118,042,102 118,042,102 43,745,988
Shareholders Funds 133,403,832 133,403,832 88,969,760
Common Size Financial Analysis Unlock full report
Accounts Date 31-Mar-2025 31-Mar-2014 31-Mar-2013
Tangible Fixed Assets - - -
Fixed Assets 27.6% 27.6% 52.7%
Stocks Inventory 3.4% 3.4% 3.5%
Debtors 9.1% 9.1% 2.5%
Cash Bank In Hand 1.9% 1.9% 5.2%
Current Assets 72.4% 72.4% 47.3%
Creditors Due Within One Year 51.2% 51.2% 62.5%
Net Current Assets Liabilities 21.2% 21.2% -15.3%
Creditors Due After One Year 2.2% 2.2% 2.8%
Accruals Deferred Income - - -
Provisions For Liabilities Charges - - -
Net Assets Liabilities Including Pension Asset Liability 46.6% 46.6% 34.6%
Called Up Share Capital 37.9% 37.9% 40.7%
Share Capital Allotted Called Up Paid 37.9% 37.9% 40.7%
Profit Loss Account Reserve -32.5% -32.5% -23.1%
Shareholder Funds 46.6% 46.6% 34.6%
Capital Employed - - -
Total Assets Less Current Liabilities 48.8% 48.8% 37.5%
Financial Ratio Analysis Unlock full report
Accounts Date 31-Mar-2025 31-Mar-2014 31-Mar-2013
Liquidity Ratio 1.4 1.4 0.8
Solvency Ratio 1.9 1.9 1.5
Reserves to Assets -0.3 -0.3 -0.2
Secured Creditors Unlock full report
Mortgages Charges 0
Mortgages Outstanding 0
Mortgages Part Satisfied 0
Mortgages Satisfied 0
Assets and Debt Analysis Unlock full report
Accounts Date 31-Mar-2025 31-Mar-2014 31-Mar-2013
Assets 286,321,314 286,321,314 256,855,410
Debt 152,917,482 152,917,482 167,885,650
Net Assets/Debt 133,403,832 133,403,832 88,969,760

The following is based on the accounts data presented in this report sourced from Companies House, however the company has filed later accounts. Our analysis of the latest account can be viewed by unlocking our full report.

The company balance sheet displays a comfortable surplus of working capital. We would normally view this positively. Total reserves including retained profitability and movement in reserves has some deficiency. The balance sheet indicates the substantial net assets of a large company. For the size of the company inferred by the balance sheet the level of net assets suggests a comfortable level of cover for total debts and obligations.

Unlock full report  The following is based on the accounts data presented in this report sourced from Companies House, however the company has filed later accounts. Our analysis of the latest account can be viewed by unlocking our full report.The company balance sheet displays a comfortable surplus of working capital. We would normally view this positively. Total reserves including retained profitability and movement in reserves has some deficiency. The balance sheet indicates the substantial net assets of a large company. For the size of the company inferred by the balance sheet the level of net assets suggests a comfortable level of cover for total debts and obligations.   The following is based on the accounts data presented in this report sourced from Companies House, however the company has filed later accounts. Our analysis of the latest account can be viewed by unlocking our full report.The company balance sheet displays a comfortable surplus of working capital. We would normally view this positively. Total reserves including retained profitability and movement in reserves has some deficiency. The balance sheet indicates the substantial net assets of a large company. For the size of the company inferred by the balance sheet the level of net assets suggests a comfortable level of cover for total debts and obligations.

This review of public record balance sheet and company status information is presented under the terms of Open Government Licence and is for informational purposes only, is general in nature, and is not intended as an opinion or advice for any specific circumstances. The commentary and the colour band score is not a credit rating or credit risk assessment.

This review does not constitute a full credit rating or credit risk assessment based on the full analysis and credit score algorithms used in our credit reports. A full credit report may also provide information relating to trade payment history and county court or court judgments if any.

Public Record Information Unlock full report
Exact Court Judgements
Period of Months Last 12m 13-24m 25-36m 37-48m 49-60m 61-72m
Number of Exact CCJS X Y Y X X Y
Value of Exact CCJS YXY YK S S X KX
Supplier Credit Limits Unlock full report
Date Sector Notified Amount Terms
XK-SXY XKXYXK SXSKXYXK £X,000 XS XYSKS
SK-SYY SKXYXKYKKY KSXX KKXXYXS £YY,000 YS XYSKS SK YXXSXS
YK-SXY XKXYXYYK SXSXYXK £SX,000 XS XYSKS
Payment Records Unlock full report
Payment Records from it's suppliers' company ledger show how a company is paying its suppliers

Payment Analysis

Total Invoices Paid Before
30 days due		 Paid After
30 days due		 Owing Before
30 days due		 Owing after
30 days due
XYX SX K YX X
Company Valuation Analysis Unlock full report

Going Concern Valuation

The going concern valuations value the company on the basis that it continues to trade without the threat of liquidation for the foreseeable future. These valuations are primarily profit and cashflow based.

Valuations Valuation Measures
Estimated High Value £XSI,000 Retained Profit £YX,000
Estimated Mid Value £YY,000 EBIT £SY,000
Estimated Low Value £X,000 EBITDA £SSX,000

Liquidation Valuation

The liquidaton valuation values the company as if it were to cease trading and assets were subject to rapid disposal to cover liabilities. This valuation is primarily asset based.

Valuations Valuation Measures
Estimated High Value £XY,000 Total Assets £XIX,000
Estimated Mid Value £Y,000 Net Assets £YX,000
Estimated Low Value £S,000 Tangible Equity £SX,000

The above valuations are based on our own algorithms and take no account of many factors that can influence actual valuations realized and should not therefore be assumed to be accurate.
Credit Status Checklist Unlock full report
Business Growth Please purchase a report to see true comments
EBITDA Purchase a report to see true comments
Dividends Please purchase a report to see true comments about this company
Retained Profits Retained Profits for this company
Debt Interest Debt Interest for this company
Cash Flow Cash Flow for this company
CCJs CCJs for this company
Age of Company Age of Company for this company
Solvency Solvency for this company
Secured Creditors Secured Creditors for this company
Ownership Ownership for this company


First Report Score: (0-10) X
Financial Status Guide:
10 Very Strong
9 Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical

Risk Score Trend

Risk Rating Unlock full report

This is the credit risk assessment used by one of the top UK credit reference agencies.

Risk Score (1-100) X
Risk Band Description XXMXMXMX SISX
Risk Assessment Meeting of Creditors
Credit Rating XSKX
Altman Z Score Credit Risk Rating Unlock full report

There have been many bankruptcy predictors developed, however none has been so thoroughly tested and broadly accepted as the Altman Z-Score.

Z Score X
Risk Band XY
Risk Band Description The Z Score is not used for small companies where full accounts are not filed because profit and loss account items are required to calculate the score.

Z Score Bands

1 Low Risk 3.00 and above
2 Caution 2.63 - 2.99
3 Risk of Failure within 2 years 1.24 - 2.62
4 High Probability Failure Below 1.24
Other Business around KT15 2NX
RACAL-NORSK LIMITED
350 Longwater Avenue, Reading, KT15 2NX
NCIPHER CORPORATION LIMITED
350 Longwater Avenue, Green Park, Reading, KT15 2NX
Document Filings
Confirmation statement made on 18 January 2026 with no updates
Termination of appointment of Sally Anne Hinchliffe as a secretary on 20 June 2025
Appointment of Mr Andrew Austen Mortlock as a director on 24 May 2025
Termination of appointment of Alan Mcdougall as a director on 31 March 2025
Statement of capital on 4 March 2025
Statement by Directors
Solvency Statement dated 04/03/25
Resolutions
Confirmation statement made on 18 January 2025 with no updates
Confirmation statement made on 18 January 2024 with no updates
Appointment of Dr Alan Mcdougall as a director on 1 September 2023
Termination of appointment of Kentaro Shimamoto as a director on 31 August 2023
Appointment of Mr Kentaro Shimamoto as a director on 2 June 2023
Termination of appointment of Keith Philip Lambert as a director on 31 May 2023
Appointment of Ms. Martina Mary Dempsey as a director on 1 April 2023
Termination of appointment of Claus Gerhard Zieler as a director on 31 March 2023
Confirmation statement made on 23 February 2023 with no updates
Notification of a person with significant control statement
Cessation of Astellas Pharma Inc. as a person with significant control on 24 February 2023
Terms and Conditions Cancellations Contact Us

In using this service you agree to the Terms and Conditions

© 2026 Check Free